Egberts TC - Search Results

1

Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases.

Vermeer NS, Straus SM, Mantel-Teeuwisse AK, Domergue F, Egberts TC, Leufkens HG, De Bruin ML. Vermeer NS, et al. Among authors: egberts tc. Drug Saf. 2013 Aug;36(8):617-25. doi: 10.1007/s40264-013-0073-3. Drug Saf. 2013. PMID: 23771794

2

Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals.

Egberts TC, Smulders M, de Koning FH, Meyboom RH, Leufkens HG. Egberts TC, et al. BMJ. 1996 Aug 31;313(7056):530-1. doi: 10.1136/bmj.313.7056.530. BMJ. 1996. PMID: 8789980 Free PMC article. No abstract available.

3

Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin.

Mantel-Teeuwisse AK, Klungel OH, Egberts TC, Verschuren WM, Porsius AJ, de Boer A. Mantel-Teeuwisse AK, et al. Among authors: egberts tc. Drug Saf. 2004;27(1):63-70. doi: 10.2165/00002018-200427010-00004. Drug Saf. 2004. PMID: 14720086

4

Risk of aplastic anemia in patients using antiepileptic drugs.

Handoko KB, Souverein PC, van Staa TP, Meyboom RH, Leufkens HG, Egberts TC, van den Bemt PM. Handoko KB, et al. Among authors: egberts tc. Epilepsia. 2006 Jul;47(7):1232-6. doi: 10.1111/j.1528-1167.2006.00596.x. Epilepsia. 2006. PMID: 16886988 Free article.

5

Changes in medication associated with epilepsy-related hospitalisation: a case-crossover study.

Handoko KB, Zwart-van Rijkom JE, Hermens WA, Souverein PC, Egberts TC. Handoko KB, et al. Among authors: egberts tc. Pharmacoepidemiol Drug Saf. 2007 Feb;16(2):189-96. doi: 10.1002/pds.1333. Pharmacoepidemiol Drug Saf. 2007. PMID: 17036373

6

Signal detection: historical background.

Egberts TC. Egberts TC. Drug Saf. 2007;30(7):607-9. doi: 10.2165/00002018-200730070-00006. Drug Saf. 2007. PMID: 17604412

7

Influence of chemical structure on hypersensitivity reactions induced by antiepileptic drugs: the role of the aromatic ring.

Handoko KB, van Puijenbroek EP, Bijl AH, Hermens WA, Zwart-van Rijkom JE, Hekster YA, Egberts TC. Handoko KB, et al. Among authors: egberts tc. Drug Saf. 2008;31(8):695-702. doi: 10.2165/00002018-200831080-00006. Drug Saf. 2008. PMID: 18636788

8

Platelet measurements versus discharge diagnoses for identification of patients with potential drug-induced thrombocytopenia: a cross-sectional study in the Netherlands.

ten Berg MJ, van Solinge WW, van den Bemt PM, Huisman A, Schobben AF, Egberts TC. ten Berg MJ, et al. Among authors: egberts tc. Drug Saf. 2009;32(1):69-76. doi: 10.2165/00002018-200932010-00006. Drug Saf. 2009. PMID: 19132806

9

Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval.

Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Egberts TC, Blackburn S, Persson I, Leufkens HG. Giezen TJ, et al. Among authors: egberts tc. Drug Saf. 2009;32(12):1175-87. doi: 10.2165/11318980-000000000-00000. Drug Saf. 2009. PMID: 19916584

10

Laboratory tests in the clinical risk management of potential drug-drug interactions: a cross-sectional study using drug-dispensing data from 100 Dutch community pharmacies.

Geerts AF, De Koning FH, De Smet PA, Van Solinge WW, Egberts TC. Geerts AF, et al. Among authors: egberts tc. Drug Saf. 2009;32(12):1189-97. doi: 10.2165/11316700-000000000-00000. Drug Saf. 2009. PMID: 19916585

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

244 results

Search Page